Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
27. Januar 2025 07:00 ET
|
Cartesian Therapeutics, Inc.
FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases
13. Januar 2025 07:00 ET
|
Cartesian Therapeutics, Inc.
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25 Deepening responses observed over time in Descartes-08-treated participants in Phase 2b trial in myasthenia...
Cartesian Therapeutics Announces New Employment Inducement Grants
07. Januar 2025 07:05 ET
|
Cartesian Therapeutics, Inc.
FREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment...
Cartesian Therapeutics Announces New Employment Inducement Grants
18. Dezember 2024 07:05 ET
|
Cartesian Therapeutics, Inc.
FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment...
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
03. Dezember 2024 06:00 ET
|
Cartesian Therapeutics, Inc.
Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points...
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
21. November 2024 07:00 ET
|
Cartesian Therapeutics, Inc.
FREDERICK, Md., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Cartesian Therapeutics Announces New Employment Inducement Grants
08. November 2024 07:05 ET
|
Cartesian Therapeutics, Inc.
FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment...
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
07. November 2024 07:00 ET
|
Cartesian Therapeutics, Inc.
Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated...
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting
05. November 2024 09:00 ET
|
Cartesian Therapeutics, Inc.
FREDERICK, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
15. Oktober 2024 07:00 ET
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...